Pharmaceutical

Biocytogen and Ona enter cancer ADC development deal

Biocytogen Pharmaceuticals and Ona Therapeutics signed an antibody agreement to develop antibody-drug conjugates for solid tumours.

Dec 18, 2023 - 10:51
Biocytogen and Ona enter cancer ADC development deal
Biocytogen Pharmaceuticals and Ona Therapeutics signed an antibody agreement to develop antibody-drug conjugates for solid tumours.
Read the original article

Tags:

Previous Article

Vertex secures CHMP nod for Casgevy approval in Europe

Next Article

CymaBay seeks FDA approval for primary biliary cholangitis therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Type 2 diabetes prevention programs can work at large scale, study finds

Type 2 diabetes prevention programs can work at large s...

Nov 15, 2023

Opinion: STAT readers on diagnostic tests, marijuana regulation, and pediatric oncology

Opinion: STAT readers on diagnostic tests, marijuana re...

Dec 9, 2023

Study shows autistic people are more likely to engage in self-harm — but not because of autism

Study shows autistic people are more likely to engage i...

Aug 9, 2023